Effect of a soymilk supplement containing isoflavones on urinary F2 isoprostane levels in premenopausal women

Sukwan Nhan, Karl Anderson, Manubai Nagamani, James J. Grady, Leejane Lu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Epidemiological studies have associated soy diets with reduced risk of breast and some other cancers, and oxidative cellular damage may contribute to the development of these and other diseases. We tested the effect of a soy milk supplement rich in isoflavones on a measure of cellular lipid peroxidation in a controlled feeding study. Eight premenopausal women consumed a constant diet that included soy-milk containing 113-207 mg/day total isoflavones and 4 mo later a constant soy diet low (<5 mg/day) in isoflavones, both for a complete menstrual cycle. The average daily urinary excretions of daidzein and genistein were 24.6 ± 10.1 and 9.2 ± 6.1 mg/day, respectively, during the high-isoflavone soy diet and were below the detection limit during the low-isoflavone diet. F2 isoprostane 8-iso-PGF-2α excretion varied widely within and between subjects, and the group mean was not significantly different during the high- and low-isoflavone soy diet (7.67 ± 1.13 and 8.65 ± 1.18 nmol/12 h, mean ± SD, respectively). However, individual changes in 8-iso-PGF-2α between the two soymilk drinks were significantly associated with age (r = -0.87; P = 0.006) and several measures of isoflavone exposure, namely, daidzein dose (r = 0.81; P = 0.015), combined daidzein and genistein dose (r = 0.77; P = 0.03), and total urinary excretion of isoflavones (daidzein, genistein, and equol) (r = 0.71; P = 0.05). The findings suggest that soy isoflavones may reduce lipid peroxidation in an age-dependent manner, with greater effects in older women, and with lower doses of isoflavones.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalNutrition and Cancer
Volume53
Issue number1
DOIs
StatePublished - 2005

Fingerprint

F2-Isoprostanes
Isoflavones
soymilk
isoflavones
daidzein
Diet
Genistein
genistein
Soy Milk
diet
excretion
Prostaglandins F
Lipid Peroxidation
lipid peroxidation
dosage
Equol
menstrual cycle
Menstrual Cycle
epidemiological studies
breasts

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Oncology
  • Food Science

Cite this

Effect of a soymilk supplement containing isoflavones on urinary F2 isoprostane levels in premenopausal women. / Nhan, Sukwan; Anderson, Karl; Nagamani, Manubai; Grady, James J.; Lu, Leejane.

In: Nutrition and Cancer, Vol. 53, No. 1, 2005, p. 73-81.

Research output: Contribution to journalArticle

@article{b157bf3d5b3745109cae4f18d559aba1,
title = "Effect of a soymilk supplement containing isoflavones on urinary F2 isoprostane levels in premenopausal women",
abstract = "Epidemiological studies have associated soy diets with reduced risk of breast and some other cancers, and oxidative cellular damage may contribute to the development of these and other diseases. We tested the effect of a soy milk supplement rich in isoflavones on a measure of cellular lipid peroxidation in a controlled feeding study. Eight premenopausal women consumed a constant diet that included soy-milk containing 113-207 mg/day total isoflavones and 4 mo later a constant soy diet low (<5 mg/day) in isoflavones, both for a complete menstrual cycle. The average daily urinary excretions of daidzein and genistein were 24.6 ± 10.1 and 9.2 ± 6.1 mg/day, respectively, during the high-isoflavone soy diet and were below the detection limit during the low-isoflavone diet. F2 isoprostane 8-iso-PGF-2α excretion varied widely within and between subjects, and the group mean was not significantly different during the high- and low-isoflavone soy diet (7.67 ± 1.13 and 8.65 ± 1.18 nmol/12 h, mean ± SD, respectively). However, individual changes in 8-iso-PGF-2α between the two soymilk drinks were significantly associated with age (r = -0.87; P = 0.006) and several measures of isoflavone exposure, namely, daidzein dose (r = 0.81; P = 0.015), combined daidzein and genistein dose (r = 0.77; P = 0.03), and total urinary excretion of isoflavones (daidzein, genistein, and equol) (r = 0.71; P = 0.05). The findings suggest that soy isoflavones may reduce lipid peroxidation in an age-dependent manner, with greater effects in older women, and with lower doses of isoflavones.",
author = "Sukwan Nhan and Karl Anderson and Manubai Nagamani and Grady, {James J.} and Leejane Lu",
year = "2005",
doi = "10.1207/s15327914nc5301_9",
language = "English (US)",
volume = "53",
pages = "73--81",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "1",

}

TY - JOUR

T1 - Effect of a soymilk supplement containing isoflavones on urinary F2 isoprostane levels in premenopausal women

AU - Nhan, Sukwan

AU - Anderson, Karl

AU - Nagamani, Manubai

AU - Grady, James J.

AU - Lu, Leejane

PY - 2005

Y1 - 2005

N2 - Epidemiological studies have associated soy diets with reduced risk of breast and some other cancers, and oxidative cellular damage may contribute to the development of these and other diseases. We tested the effect of a soy milk supplement rich in isoflavones on a measure of cellular lipid peroxidation in a controlled feeding study. Eight premenopausal women consumed a constant diet that included soy-milk containing 113-207 mg/day total isoflavones and 4 mo later a constant soy diet low (<5 mg/day) in isoflavones, both for a complete menstrual cycle. The average daily urinary excretions of daidzein and genistein were 24.6 ± 10.1 and 9.2 ± 6.1 mg/day, respectively, during the high-isoflavone soy diet and were below the detection limit during the low-isoflavone diet. F2 isoprostane 8-iso-PGF-2α excretion varied widely within and between subjects, and the group mean was not significantly different during the high- and low-isoflavone soy diet (7.67 ± 1.13 and 8.65 ± 1.18 nmol/12 h, mean ± SD, respectively). However, individual changes in 8-iso-PGF-2α between the two soymilk drinks were significantly associated with age (r = -0.87; P = 0.006) and several measures of isoflavone exposure, namely, daidzein dose (r = 0.81; P = 0.015), combined daidzein and genistein dose (r = 0.77; P = 0.03), and total urinary excretion of isoflavones (daidzein, genistein, and equol) (r = 0.71; P = 0.05). The findings suggest that soy isoflavones may reduce lipid peroxidation in an age-dependent manner, with greater effects in older women, and with lower doses of isoflavones.

AB - Epidemiological studies have associated soy diets with reduced risk of breast and some other cancers, and oxidative cellular damage may contribute to the development of these and other diseases. We tested the effect of a soy milk supplement rich in isoflavones on a measure of cellular lipid peroxidation in a controlled feeding study. Eight premenopausal women consumed a constant diet that included soy-milk containing 113-207 mg/day total isoflavones and 4 mo later a constant soy diet low (<5 mg/day) in isoflavones, both for a complete menstrual cycle. The average daily urinary excretions of daidzein and genistein were 24.6 ± 10.1 and 9.2 ± 6.1 mg/day, respectively, during the high-isoflavone soy diet and were below the detection limit during the low-isoflavone diet. F2 isoprostane 8-iso-PGF-2α excretion varied widely within and between subjects, and the group mean was not significantly different during the high- and low-isoflavone soy diet (7.67 ± 1.13 and 8.65 ± 1.18 nmol/12 h, mean ± SD, respectively). However, individual changes in 8-iso-PGF-2α between the two soymilk drinks were significantly associated with age (r = -0.87; P = 0.006) and several measures of isoflavone exposure, namely, daidzein dose (r = 0.81; P = 0.015), combined daidzein and genistein dose (r = 0.77; P = 0.03), and total urinary excretion of isoflavones (daidzein, genistein, and equol) (r = 0.71; P = 0.05). The findings suggest that soy isoflavones may reduce lipid peroxidation in an age-dependent manner, with greater effects in older women, and with lower doses of isoflavones.

UR - http://www.scopus.com/inward/record.url?scp=30444437174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444437174&partnerID=8YFLogxK

U2 - 10.1207/s15327914nc5301_9

DO - 10.1207/s15327914nc5301_9

M3 - Article

C2 - 16351509

AN - SCOPUS:30444437174

VL - 53

SP - 73

EP - 81

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 1

ER -